The European Commission approved Novartis’ Mayzent for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
The U.S. Food and Drug Administration approved Vumerity (diroximel fumarate) – a novel oral fumarate with a distinct chemical structure – for the treatment of relapsing forms of multiple sclerosis.
EMD Serono, a unit of Merck KGaA, announced that the U.S. FDA approved Mavenclad (cladribine) for adults with relapsing-remitting multiple sclerosis and active secondary progressive disease.
Roche company Genentech has released data from a long-term clinical trial of Ocrevus (ocrelizumab) in multiple sclerosis. The U.S. FDA and the European Medicines Agency accepted Novartis’ marketing applications for siponimod (BAF312) to treat secondary-progressive multiple sclerosis in adults.
The U.S. FDA accepted Novartis’ New Drug Application for the investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.
Novartis announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis were published in the peer-reviewed journal The Lancet.
Novartis, lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionizing cancer treatment, is focusing on the next wave of immune system-boosting medicines.
In the wake of a failed Phase IIb clinical trial, Opexa Therapeutics announced it will be laying off about 40 percent of its workforce.
Novartis AG said a late-stage study showed its oral once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.
November 5, 2015By Mark Terry, BioSpace.com Breaking News Staff After Cambridge, Mass.-based Biogen, Inc. (BIIB) presented its research and development ambitions on Tuesday, analysts have started examining the company’s […]
